deltatrials
Completed PHASE3 NCT00056407

REDUCE - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5 mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer

Sponsor: GlaxoSmithKline

Conditions Neoplasms, Prostate
Interventions Dutasteride Placebo
Updated 7 times since 2017 Last updated: Aug 17, 2016 Started: Mar 31, 2003 Primary completion: Jan 31, 2009 Completion: Apr 30, 2009

A PHASE3 clinical study on Neoplasms, Prostate, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 7 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

7 versions recorded

  1. Oct 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands, Aachen, Germany, Aalst, Belgium, Aarau, Switzerland, Aberdeen, United Kingdom, Adelaide, Australia, Ahrensburg, Germany, Aichach, Germany, Alava, Spain, Albany, United States and 722 more location s